Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Abstract Acute myeloid leukemia (AML) and DNMT3A mutations (DNMT3A mut) are considered to carry intermediate risk under the 2022 European LeukemiaNet (ELN-2022) classification in the absence of other co-mutations or cytogenetic abnormalities. However, this group is highly heterogeneous. In this stud...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, Min-Yen Lo, Chien-Yuan Chen, Wan-Hsuan Lee, Chien-Chin Lin, Yuan-Yeh Kuo, Yen-Ling Peng, Mei-Hsuan Tseng, Yu-Sin Wu, Ming-Chih Liu, Liang-In Lin, Ming-Kai Chuang, Bor-Sheng Ko, Ming Yao, Jih-Luh Tang, Feng-Ming Tien, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Publishing Group 2025-05-01
Edice:	Blood Cancer Journal
On-line přístup:	https://doi.org/10.1038/s41408-025-01287-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!